Interestingly, expression of MRPL4 was found to have a greater association with high-risk samples than AMACR, an established biomarker of prostate cancer [72], with MRPL4 overexpression also associated with increased mortality and poorer survival [45, 72]. Here, MRPL4 is linked to prostate carcinoma.